A psychiatrist’s reference guide to the medications your clients are taking — and how understanding them makes you a more effective therapist.
If you’re a licensed therapist, you’ve almost certainly had a client say something like: “My psychiatrist just started me on Zoloft — is that going to change how I feel in therapy?” Or perhaps: “I stopped taking my medication because I read online that antidepressants are addictive.”
These moments matter. You don’t need to be a prescriber to help your clients navigate the medication experience, but a working knowledge of psychopharmacology basics for therapists can make you a significantly more effective clinician. When you understand what psychiatric medications do — and what they don’t — you’re better positioned to support adherence, manage expectations, and collaborate meaningfully with your client’s prescriber.
This guide covers the major medication classes used in outpatient psychiatry, written specifically for therapists who want a practical, bookmark-worthy reference for medication management in mental health settings.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressants and often the first medication a psychiatrist will consider for depression, generalized anxiety, panic disorder, OCD, PTSD, and social anxiety disorder. Understanding the SSRI vs SNRI distinction is one of the most common questions therapists encounter.
Common SSRIs include sertraline (Zoloft), fluoxetine (Prozac), escitalopram (Lexapro), paroxetine (Paxil), citalopram (Celexa), and fluvoxamine (Luvox).
SSRIs block the reabsorption (reuptake) of serotonin in the brain, making more serotonin available in the synaptic cleft. This doesn’t “add” serotonin — it allows the serotonin already being produced to remain active longer. Over weeks, this triggers downstream neuroplastic changes that are thought to be responsible for the therapeutic effect.
This is critical information for therapists: SSRIs typically take 4 to 6 weeks to reach full therapeutic effect. Some patients notice initial changes (positive or negative) within 1–2 weeks, but premature discontinuation is one of the most common reasons medications “don’t work.” If your client reports no change at week two, that’s expected — not a treatment failure.
Emotional blunting — the sense that both highs and lows are muted — is a frequent complaint that clients may bring to therapy rather than to their psychiatrist. If a client describes feeling “flat” or “numb,” this is clinically relevant feedback worth communicating to the prescriber. It may indicate the need for a dosage adjustment or a switch to a different medication.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) work on two neurotransmitter systems rather than one. They’re commonly prescribed for depression that hasn’t responded to SSRIs, generalized anxiety disorder, chronic pain conditions, and fibromyalgia.
Common SNRIs include venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq).
Like SSRIs, SNRIs block serotonin reuptake — but they also block norepinephrine reuptake. Norepinephrine is involved in alertness, energy, and pain modulation. This dual mechanism is why SNRIs are sometimes chosen when a patient has both mood symptoms and chronic pain, or when fatigue and low motivation are prominent features.
The most common question therapists ask is how SSRIs and SNRIs differ in practice. The primary distinction is the addition of norepinephrine activity. SNRIs may be more activating and may help with pain-related symptoms, but they also carry a somewhat different side effect profile — including potential blood pressure elevation with venlafaxine and a more pronounced discontinuation syndrome. Venlafaxine, in particular, has a short half-life, meaning missed doses can quickly produce withdrawal-like symptoms.
Not all antidepressants fit neatly into the SSRI/SNRI categories. Two atypical antidepressants come up frequently in clinical practice.
Bupropion works primarily on dopamine and norepinephrine — not serotonin. This makes it unique among antidepressants and gives it a distinct clinical profile:
Therapists should know that bupropion is frequently combined with an SSRI when sexual side effects are problematic or when the SSRI alone provides incomplete response. If your client mentions being on “two antidepressants,” this combination is one of the most common and is not cause for alarm.
Mirtazapine has a unique mechanism involving norepinephrine and serotonin modulation through different receptor pathways than SSRIs/SNRIs.
If a client reports their psychiatrist prescribed mirtazapine specifically to help with sleep and appetite, this is an intentional use of the medication’s side effect profile — a common and thoughtful prescribing strategy.
Mood stabilizers are primarily associated with bipolar disorder, but they’re also used for mood dysregulation, impulsivity, and as augmentation strategies in treatment-resistant depression. The major mood stabilizers include lithium, valproic acid (Depakote), lamotrigine (Lamictal), and carbamazepine (Tegretol).
Lithium remains the gold standard for bipolar disorder and has unique anti-suicidal properties not shared by other mood stabilizers. However, it requires regular blood level monitoring and can affect thyroid and kidney function over time. If your client is on lithium, they should be getting regular lab work.
Lamotrigine (Lamictal) is increasingly popular because it’s well-tolerated, doesn’t cause weight gain, and is effective for bipolar depression — historically one of the hardest presentations to treat. The main concern is a rare but serious skin reaction (Stevens-Johnson syndrome), which is why it must be titrated very slowly over several weeks. If your client mentions a new rash while starting lamotrigine, encourage them to contact their prescriber immediately.
Valproic acid (Depakote) is effective for mania but carries more side effects, including weight gain, hair thinning, and tremor. It also requires blood monitoring and is contraindicated in pregnancy due to teratogenic effects.
Mood stabilizers vary widely. Lithium and valproic acid can show antimanic effects within days to a week. Lamotrigine, due to its required slow titration, may take 6–8 weeks to reach a therapeutic level.
The term “antipsychotic” often alarms clients and therapists alike, but second-generation (atypical) antipsychotics are frequently used at low doses for conditions far removed from psychosis. These include quetiapine (Seroquel), aripiprazole (Abilify), olanzapine (Zyprexa), risperidone (Risperdal), and lurasidone (Latuda).
When a client says “my doctor put me on an antipsychotic,” they may be frightened or confused. Understanding that these medications are routinely used at low doses for depression augmentation, sleep, and mood stabilization allows you to normalize the experience and reduce stigma. The prescriber likely chose it for a very specific, non-psychotic indication.
Akathisia deserves special mention: clients experiencing it may describe feeling “crawling out of my skin,” restless, or unable to relax. This can look like worsening anxiety but is actually a medication side effect. If you hear these descriptions shortly after a medication change, flag it for the prescriber.
Stimulant medications are the most effective pharmacological treatment for ADHD. They include methylphenidate-based medications (Ritalin, Concerta, Focalin) and amphetamine-based medications (Adderall, Vyvanse, Dexedrine).
Stimulants increase dopamine and norepinephrine availability in the prefrontal cortex, improving executive function, attention, and impulse control. Despite the name “stimulant,” they don’t make people with ADHD “hyper” — they enhance the brain’s ability to regulate attention and behavior.
Unlike antidepressants, stimulants work on the day they’re taken. Effects begin within 30–60 minutes and last 4–12 hours depending on the formulation (immediate-release vs. extended-release). There is no weeks-long “ramp up” period.
ADHD medication is not a substitute for skills training, organizational strategies, or therapy addressing the emotional impact of living with ADHD. The best outcomes come from combined treatment — medication to improve the brain’s capacity for focus, and therapy to build the habits and self-awareness that executive dysfunction has disrupted. You play a critical role in this equation.
Also be aware that some clients may experience a “grief response” after starting stimulant medication: “If I’d had this 20 years ago, my life might have been so different.” This is therapeutically important material.
Benzodiazepines — including alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), and diazepam (Valium) — are fast-acting anti-anxiety medications that work by enhancing the effect of GABA, the brain’s primary inhibitory neurotransmitter.
Benzodiazepines provide rapid relief for acute anxiety and panic, which makes them highly reinforcing for patients. However, they carry significant risks with long-term use:
Most psychiatrists today use benzodiazepines sparingly — as short-term bridges while SSRIs or SNRIs take effect, or as occasional “as-needed” medications for acute panic. If a client is taking benzodiazepines daily on a long-term basis, this may warrant a conversation with the prescriber about the treatment plan, particularly if you’re doing exposure-based work. Your clinical observations about a client’s reliance patterns are invaluable data for the prescribing team.
Effective psychiatric medication management in mental health requires collaboration. When you have the client’s consent for communication, here are questions that foster productive dialogue with the prescriber:
These questions demonstrate your professionalism and investment in integrated care. Most psychiatrists deeply appreciate therapists who engage at this level.
Clients arrive in therapy with beliefs about psychiatric medication shaped by internet searches, social media, well-meaning friends, and cultural narratives. Here are the most common myths and evidence-based reframes:
Antidepressants do not produce euphoria, cravings, or compulsive use — the hallmarks of addiction. Some antidepressants (particularly SSRIs, SNRIs, and paroxetine especially) can cause discontinuation syndrome if stopped abruptly, which involves physical discomfort but is physiologically distinct from addiction. The appropriate language is “physical dependence” in some cases, not addiction. Tapering under medical supervision prevents discontinuation symptoms.
This belief often carries deep shame. A useful reframe: medication can create the neurochemical conditions that allow therapy to work more effectively. No one calls insulin a “crutch” for diabetes. For moderate-to-severe depression, the combination of medication and psychotherapy consistently outperforms either treatment alone in research.
This is one of the most dangerous myths. Feeling better is often evidence that the medication is working, not that it’s no longer needed. For a first depressive episode, guidelines typically recommend continuing medication for at least 6–12 months after remission. For recurrent depression, maintenance treatment may be indefinite. Stopping prematurely is the leading cause of relapse.
Effective treatment shouldn’t erase personality — it should remove the illness that’s obscuring it. If a client feels like a “different person” in a negative way (flat, disconnected, emotionally numb), that’s a side effect worth reporting, not an inevitable consequence of treatment. The goal is to feel like themselves again, not like someone else.
The “natural equals safe” assumption overlooks that supplements are unregulated, may have variable potency, and can interact dangerously with prescribed medications. St. John’s Wort, for example, interacts with SSRIs and can cause serotonin syndrome — a potentially life-threatening condition. Clients should always disclose supplement use to their prescriber.
Many clients fear that starting medication means a lifetime commitment. While some individuals benefit from long-term maintenance, many others use medication for a defined period — through a depressive episode, during a life transition, while building coping skills in therapy — and then taper off successfully. The decision is individualized and collaborative, not predetermined.
As a therapist, you occupy a unique position in your client’s care. You spend more time with them than any other provider. You hear how they describe their inner experience in ways that a 15-minute medication check cannot capture. Your observations about mood patterns, side effects, adherence barriers, and functional changes are clinically invaluable.
You don’t need to be an expert in psychopharmacology to be an excellent collaborator in your client’s psychiatric care. What you need is:
This psychiatric medications guide for therapists is meant to be a starting point. The best learning comes from the ongoing dialogue between you, your clients, and their prescribers — the kind of integrated care that produces the best outcomes for everyone involved.
Dr. Ronald Lee is a board-certified psychiatrist practicing telepsychiatry in Massachusetts. He works closely with therapists to provide integrated psychiatric care. For clinicians interested in collaborative care, he can be reached at luminousvitalitybh.com.
Request an initial appointment by clicking the Appointment Bot to register for the patient portal--or call for help!
You are NOT financially committed to anything until you enter your payment information AND your appointment is confirmed!!
Please complete the form below for any questions. Request an Appointment for the quickest and most efficient way.
One Boston Place, 201 Washington St. Suite 2679, Boston, MA 02108
(Virtual Office Address as LVBH is Boston Based but Servicing All Areas/Residents of MA via Telemedicine)
